Upon arriving at Shanghai, the team hosted a conference attended by Shanghai Municipal People's Congress, courts, government departments and some representatives of Academies. The relevant issues discussed in the conference include the mechanism for the patent system promoting independent innovation, the improvement of Service Invention system, the patent administrative enforcement, the management of patent and the improvement of the procedure of patent litigation etc. Meanwhile, some attendees proposed lots of constructive suggestions in respect of the revision of the current patent law.

The Basic Terms includes and standardizes 105 items in the IP field and unifies both the terms in Chinese and English, such as general IP terms, patent terms, trademark terms and copyright terms, which are applicable to relevant IP literature and information fields. Classification and Code adopts digital encoding methods to work out a classification system based on the characteristics of literature information in the IP field, including 5 categories of general introduction, patent, trademark, copyright and other IP rights or related protection and 139 items, applicable to the classification and mark of IP literature and information, but inapplicable to the classification of patent literature and trademark gazettes.

It is reported that the two standards are being recommended to intellectual property systems at all levels nationwide.

Ms. Yang registered the domain name of “辉瑞大连” (Pfizer Dalian in Chinese). Pfizer believed that Ms. Yang’s registration of the said domain name without its permission had constituted infringement. Pfizer therefore filed a lawsuit before Dalian Middle Court, claiming that in accordance with laws, “Pfizer in Chinese” shall be recognized as a well-known trademark. Pfizer further requested Ms. Yang to stop using of the contested domain name, remove it from the Registry, and compensate RMB 5,000 as economic losses.

Dalian Middle Court ordered Ms. Yang to stop using the contested domain name and remove it from the Registry immediately, but rejected Pfizer’s other requests. The litigation costs shall be paid by Ms. Yang. As Pfizer and Ms. Yang did not appeal, the judgment of the case is uncontested and has been enforced.

The Compendium emphasizes that China will improve the trial system for intellectual property, optimize the allocation of judicial resources and simplify the remedy procedures. It points out that studies need to be carried out on establishing special tribunals to handle civil, administrative or criminal cases involving intellectual property. Studies also need to be done to reasonably centralize jurisdiction over cases involving patents or other cases of a highly technical nature. Moreover, China will explore issues on setting up courts of appeal for cases involving intellectual property. Judicial organs for handling cases involving intellectual property need to be further strengthened and well-staffed to improve the handling of cases and enforcement of the law.

The attendees discussed on company creation, enterprises’ operation, international cooperation and intellectual property strategy in the biotech field in China. The seminar aims at enhancing cross border communication between investors, enterprisers and legal counselors domestic and overseas. More than 50 enterprises’ and organizations’ chiefs of related fields attended the seminar. Also, the attendees participated in discussions with the honorable guests and main lecturers.

Dr. Charles C. Liu, main speaker of the Seminar, made an insightful speech on inventions and its patent protection in chemistry and biology fields, with many diagrams and examples. Mr. Greg. B, Scott, Dr. Faming Zhang and Mr. John K. Liu made incisive speeches separately on how to attract investment fund, lower the costs for research and development on medicine, and construction of an internationalized company.

The attendees made in-depth discussions on the following topics for biotech creators: how to prepare funds, construct an internationalized company, and plan internal patent strategies. The attendees communicated with the guest speakers actively, and said that they benefit a lot from the Seminar. The Seminar provided a face-to-face opportunity for domestic and overseas experts to communicate. Also, it served to build a bridge for biotech enterprises in China to go into the world, as expressed by the slogan of ChinaBio.

(For details, please contact us)